Tom Powles, Head of Solid Tumor Research at Barts Cancer Institute, shared on X:
“5 year efficacy and biomarker data for Axitinib/Pembrolizumab in 1st line clear cell RCC.
Significant RR PFS and OS in the ITT population means this combo is as good as any in this setting. None of the biomarkers tested (RNA, DNA PR) will change clinical practice.
Perhaps the most consistent biomarkers tested are the RNA angiogenic signature for sunitinib and the RNA activated T cell signature for axi/pembro. The positive PBRM1 results are speculative, while the negative PD-L1 results focus on the CPS rather than TC methods in CARE1.”
More posts featuring Tom Powles.
